CMS’s Proposed Rule On Value-Based Purchasing For Prescription Drugs: New Tools For Negotiating Prices For The Next Generation of Therapies | Health Affairs

CMS’s Proposed Rule On Value-Based Purchasing For Prescription Drugs: New Tools For Negotiating Prices For The Next Generation of Therapies | Health Affairs

Published by Health Affairs on June 18, 2020 

Contact: CMS Media Relations
(202) 690-6145 | CMS Media Inquiries

CMS’s Proposed Rule On Value-Based Purchasing For Prescription Drugs: New Tools For Negotiating Prices For The Next Generation of Therapies

The Trump Administration has delivered significant policy advancements to lower the price of drugs and spur greater competition and innovation in the American health care system. As a result of actions by the Centers for Medicare and Medicaid Services (CMS), the average basic premium for Medicare Part D prescription drug plans was projected to decline 13.5 percent since 2017, to the lowest level in seven years, saving beneficiaries about $1.9 billion in premium costs over that time. Most recently, in March, CMS announced the Senior Savings Model, where participating enhanced Part D prescription drug plans across the country will provide Medicare beneficiaries access to a broad set of insulins at a maximum $35 copay for a month’s supply, saving beneficiaries on average 66 percent per year.

Today, we are announcing another significant step in this fight through a proposed overhaul of Medicaid regulations that have long inhibited payment innovation among prescription drugs across the entire system. 

To read the full Health Affairs blog, go to:

https://www.healthaffairs.org/do/10.1377/hblog20200617.728496/full/